Paradigm Biopharmaceuticals Selects Clinical Research Organization for Osteoarthritis Trial; Shares Up 4%

MT Newswires Live

01/31

Paradigm Biopharmaceuticals (ASX:PAR) selected Advanced Clinical as its preferred partner for a phase 3 clinical trial evaluating the dose and treatment effect of injectable pentosan polysulfate sodium in knee osteoarthritis pain, according to a Friday filing with the Australian bourse.

The company expects to receive centralized ethics approval for Australia soon, with the first sites to be activated in Victoria and up to 10 sites across the country, per the filing. The dosing of the first participant is anticipated in the second quarter of the year.

Paradigm Biopharmaceuticals shares rose nearly 4% in midday trade Friday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2507977983"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507977983\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2507977983?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-31 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507977983","market":"us","top_or_hot":-1,"title":"Paradigm Biopharmaceuticals Selects Clinical Research Organization for Osteoarthritis Trial; Shares Up 4%","media":"MT Newswires Live","content":"<html><body><p> Paradigm Biopharmaceuticals (ASX:PAR) selected Advanced Clinical as its preferred partner for a phase 3 clinical trial evaluating the dose and treatment effect of injectable pentosan polysulfate sodium in knee osteoarthritis pain, according to a Friday filing with the Australian bourse.</p><p>The company expects to receive centralized ethics approval for Australia soon, with the first sites to be activated in Victoria and up to 10 sites across the country, per the filing. The dosing of the first participant is anticipated in the second quarter of the year.</p><p>Paradigm Biopharmaceuticals shares rose nearly 4% in midday trade Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Biopharmaceuticals Selects Clinical Research Organization for Osteoarthritis Trial; Shares Up 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Biopharmaceuticals Selects Clinical Research Organization for Osteoarthritis Trial; Shares Up 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-31 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Paradigm Biopharmaceuticals (ASX:PAR) selected Advanced Clinical as its preferred partner for a phase 3 clinical trial evaluating the dose and treatment effect of injectable pentosan polysulfate sodium in knee osteoarthritis pain, according to a Friday filing with the Australian bourse.</p><p>The company expects to receive centralized ethics approval for Australia soon, with the first sites to be activated in Victoria and up to 10 sites across the country, per the filing. The dosing of the first participant is anticipated in the second quarter of the year.</p><p>Paradigm Biopharmaceuticals shares rose nearly 4% in midday trade Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507977983","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507977983","pubTimestamp":1738287219,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  selected Advanced Clinical as its preferred partner for a phase 3 clinical trial evaluating the dose and treatment effect of injectable pentosan polysulfate sodium in knee osteoarthritis pain, according to a Friday filing with the Australian bourse.The company expects to receive centralized ethics approval for Australia soon, with the first sites to be activated in Victoria and up to 10 sites across the country, per the filing. The dosing of the first participant is anticipated in the second quarter of the year.Paradigm Biopharmaceuticals shares rose nearly 4% in midday trade Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","PAR.AU":"PARADIGM BIOPHARMACEUTICALS","XKO.AU":"标普/澳交所 300指数","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","BK7508":"医药生物股"},"translate_title":"Paradigm Biopharmaceuticals选择临床研究机构进行骨关节炎试验；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":0.9,"XKO.AU":0.87,"XJO.AU":0.87,"XAO.AU":0.87},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) selected Advanced Clinical as its preferred partner for a phase 3 clinical trial evaluating the dose and treatment effect of injectable pentosan polysulfate sodium in knee osteoarthritis pain, according to a Friday filing with the Australian bourse.The company expects to receive centralized ethics approval for Australia soon, with the first sites to be activated in Victoria and up to 10 sites across the country, per the filing. The dosing of the first participant is anticipated in the second quarter of the year.Paradigm Biopharmaceuticals shares rose nearly 4% in midday trade Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}